1. Home
  2. BGSF vs ENTX Comparison

BGSF vs ENTX Comparison

Compare BGSF & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BGSF Inc.

BGSF

BGSF Inc.

HOLD

Current Price

$5.70

Market Cap

65.8M

ML Signal

HOLD

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.17

Market Cap

62.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGSF
ENTX
Founded
2007
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.8M
62.6M
IPO Year
2013
2015

Fundamental Metrics

Financial Performance
Metric
BGSF
ENTX
Price
$5.70
$1.17
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
20.3K
173.8K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
34.84%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.25
Revenue
$93,310,000.00
$42,000.00
Revenue This Year
$4.67
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$4.52
Revenue Growth
N/A
N/A
52 Week Low
$2.91
$0.91
52 Week High
$8.20
$3.22

Technical Indicators

Market Signals
Indicator
BGSF
ENTX
Relative Strength Index (RSI) 46.28 48.33
Support Level $5.92 $1.17
Resistance Level $6.38 $1.61
Average True Range (ATR) 0.30 0.14
MACD -0.06 0.01
Stochastic Oscillator 42.86 56.25

Price Performance

Historical Comparison
BGSF
ENTX

About BGSF BGSF Inc.

BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: